$2.6 Billion is the total value of Avoro Capital Advisors LLC's 44 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $136,918,000 | – | 489,536 | +100.0% | 5.27% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $126,751,000 | – | 958,928 | +100.0% | 4.88% | – |
| PTCT | New | PTC THERAPEUTICS INC | $77,406,000 | – | 2,294,877 | +100.0% | 2.98% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $71,679,000 | – | 3,419,818 | +100.0% | 2.76% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $68,953,000 | – | 700,100 | +100.0% | 2.65% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $42,433,000 | – | 4,471,300 | +100.0% | 1.63% | – |
| TCDA | New | TRICIDA INC | $32,763,000 | – | 1,095,764 | +100.0% | 1.26% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $17,209,000 | – | 1,282,374 | +100.0% | 0.66% | – |
| SESN | New | SESEN BIO INC | $13,260,000 | – | 6,800,000 | +100.0% | 0.51% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $11,059,000 | – | 1,202,118 | +100.0% | 0.43% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS INC | $6,120,000 | – | 450,000 | +100.0% | 0.24% | – |
| AVRO | New | AVROBIO INC | $2,856,000 | – | 100,000 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.